Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Pavel Souček

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4294-6799; OpenAlex author ID A5090756163. Sources: OpenAlex.

Their work

Papers
54 (first author 3, last author 12)
Trials
0
Grants
0
Labs led
2
Collaborators
104
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 5 papers · 2014: 2 papers · 2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: 2 papers · 2019: 7 papers · 2020: 1 paper · 2021: 8 papers · 2022: 3 papers · 2023: 7 papers · 2024: 3 papers · 2025: 6 papers

Papers 50 of 54

  1. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  2. Potential for Clinical Management of Pancreatic Cancer Through Whole Exome Profiling of Site-Specific Metastases and Matched Primary Tumors. Last author DOI 10.1016/j.labinv.2025.104205↗
  3. The relationship of the microbiome, associated metabolites and the gut barrier with pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.03.002↗
  4. Therapeutic pancreatic cancer biomarkers and pharmacogenetics. First author DOI 10.1016/j.semcancer.2025.08.002↗
  5. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  6. Determinants of Implantation Success in Pancreatic Cancer Patient-Derived Xenografts: Role of Matrigel Application, Histological Subtype, and Time Management. Co-author DOI 10.14712/fb2025.0006↗
  7. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  8. Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2024.109044↗
  9. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  10. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  11. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  12. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  13. Protein expression and localization of ABC transporters in pancreatic adenocarcinoma: Prognostic role of ABCC8. Last author DOI 10.1016/j.pan.2023.10.008↗
  14. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  15. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  16. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  17. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  18. Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens Co-author DOI 10.33699/pis.2022.101.12.584-592↗
  19. Laser Capture Microdissection: A Gear for Pancreatic Cancer Research. First author DOI 10.3390/ijms232314566↗
  20. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  21. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  22. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  23. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  24. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  25. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  26. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  27. Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer. Last author DOI 10.3892/ol.2021.12859↗
  28. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  29. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  30. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  31. Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma. Last author DOI 10.1038/s41598-019-56059-w↗
  32. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  33. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. Last author DOI 10.1093/mutage/gez021↗
  34. Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alteration… Co-author DOI 10.2147/cmar.s185352↗
  35. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Co-author DOI 10.2217/pgs-2018-0073↗
  36. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  37. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Last author DOI 10.1038/s41467-018-02942-5↗
  38. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Last author DOI 10.1038/srep43812↗
  39. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Last author DOI 10.1038/tpj.2016.55↗
  40. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  41. Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. Co-author DOI 10.1016/j.cancergen.2016.03.003↗
  42. The c.657del5 variant in the NBN gene predisposes to pancreatic cancer. Co-author DOI 10.1016/j.gene.2016.04.056↗
  43. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  44. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  45. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  46. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  47. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  48. Role of solute carrier transporters in pancreatic cancer: a review. First author DOI 10.2217/pgs.14.80↗
  49. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Last author DOI 10.1007/s00280-013-2246-2↗
  50. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beatrice Mohelníková-Duchoňová · 21 shared papers, 2011–2025 · strength 1.88
  2. Martin Oliverius · 12 shared papers, 2013–2025 · strength 1.13
  3. Daniele Campa · 11 shared papers, 2013–2025 · strength 1.02
  4. Viktor Hlaváč · 7 shared papers, 2013–2025 · strength 0.98
  5. Cosmeri Rizzato · 7 shared papers, 2013–2025 · strength 0.66
  6. Martin Loveček · 6 shared papers, 2017–2025 · strength 0.65
  7. Riccardo Farinella · 3 shared papers, 2023–2025 · strength 0.62
  8. Árpád Szabó · 3 shared papers, 2022–2025 · strength 0.55
  9. Tomas Sychra · 3 shared papers, 2022–2025 · strength 0.55
  10. Lenka Červenková · 3 shared papers, 2019–2025 · strength 0.52
  11. Federico Canzian · 9 shared papers, 2013–2023 · strength 0.52
  12. Gabriele Capurso · 9 shared papers, 2013–2023 · strength 0.52
  13. Raffaele Pezzilli · 9 shared papers, 2013–2023 · strength 0.52
  14. Francesca Tavano · 7 shared papers, 2013–2023 · strength 0.47
  15. Aleš Langer · 2 shared papers, 2025 · strength 0.46
  16. John P. Neoptolemos · 7 shared papers, 2013–2023 · strength 0.44
  17. David J. Hughes · 4 shared papers, 2017–2025 · strength 0.42
  18. Renata Talar‐Wojnarowska · 8 shared papers, 2013–2022 · strength 0.41
  19. Pavel Vodička · 7 shared papers, 2013–2023 · strength 0.38
  20. Giulia Martina Cavestro · 4 shared papers, 2019–2023 · strength 0.36
  21. Manuel Gentiluomo · 4 shared papers, 2019–2023 · strength 0.36
  22. Zdeněk Kala · 6 shared papers, 2013–2021 · strength 0.35
  23. Thilo Hackert · 5 shared papers, 2016–2023 · strength 0.35
  24. Bohuslav Melichar · 5 shared papers, 2013–2019 · strength 0.35
  25. Ștefania Bunduc · 2 shared papers, 2023–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.